Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. Among authors: domingo p. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Podzamczer D, Miró JM, Bolao F, Gatell JM, Cosín J, Sirera G, Domingo P, Laguna F, Santamaría J, Verdejo J. Podzamczer D, et al. Among authors: domingo p. Ann Intern Med. 1995 Aug 1;123(3):175-80. doi: 10.7326/0003-4819-123-3-199508010-00003. Ann Intern Med. 1995. PMID: 7598298 Clinical Trial.
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Martínez E, et al. Among authors: domingo p. N Engl J Med. 2003 Sep 11;349(11):1036-46. doi: 10.1056/NEJMoa021589. N Engl J Med. 2003. PMID: 12968087 Free article. Clinical Trial.
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V. Barrios A, et al. Among authors: domingo p. AIDS. 2005 Mar 24;19(6):569-75. doi: 10.1097/01.aids.0000163933.14649.93. AIDS. 2005. PMID: 15802975 Clinical Trial.
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V; EFADITE Study Group. Barrios A, et al. Among authors: domingo p. Antivir Ther. 2005;10(7):825-32. Antivir Ther. 2005. PMID: 16312178 Clinical Trial.
758 results